227 related articles for article (PubMed ID: 30390071)
1. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.
Frazier NM; Brand T; Gordan JD; Grandis J; Jura N
Oncogene; 2019 Mar; 38(11):1936-1950. PubMed ID: 30390071
[TBL] [Abstract][Full Text] [Related]
2. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
Tanizaki J; Okamoto I; Sakai K; Nakagawa K
Br J Cancer; 2011 Sep; 105(6):807-13. PubMed ID: 21847121
[TBL] [Abstract][Full Text] [Related]
3. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
[TBL] [Abstract][Full Text] [Related]
4. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
5. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.
Yun C; Gang L; Rongmin G; Xu W; Xuezhi M; Huanqiu C
Mol Carcinog; 2015 Dec; 54(12):1700-9. PubMed ID: 25400108
[TBL] [Abstract][Full Text] [Related]
6. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
7. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
8. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
9. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
Ma J; Lyu H; Huang J; Liu B
Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
[TBL] [Abstract][Full Text] [Related]
10. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
11. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
12. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.
van Lengerich B; Agnew C; Puchner EM; Huang B; Jura N
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2836-E2845. PubMed ID: 28320942
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
14. M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.
Ohashi Y; Okamura M; Hirosawa A; Tamaki N; Akatsuka A; Wu KM; Choi HW; Yoshimatsu K; Shiina I; Yamori T; Dan S
Cancer Res; 2016 Jul; 76(13):3895-903. PubMed ID: 27197184
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of the pseudokinase Her3.
Xie T; Lim SM; Westover KD; Dodge ME; Ercan D; Ficarro SB; Udayakumar D; Gurbani D; Tae HS; Riddle SM; Sim T; Marto JA; Jänne PA; Crews CM; Gray NS
Nat Chem Biol; 2014 Dec; 10(12):1006-12. PubMed ID: 25326665
[TBL] [Abstract][Full Text] [Related]
16. SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.
Jenke R; Holzhäuser-Rein M; Mueller-Wilke S; Lordick F; Aigner A; Büch T
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374770
[TBL] [Abstract][Full Text] [Related]
17. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
18. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
[TBL] [Abstract][Full Text] [Related]
19. Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.
Ayoub MA; See HB; Seeber RM; Armstrong SP; Pfleger KD
PLoS One; 2013; 8(5):e64672. PubMed ID: 23700486
[TBL] [Abstract][Full Text] [Related]
20. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
